glp 1 gip agonists LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept GLP-1 and Dual GIP/GLP-1 Agonists

(30,31) The authors acknowledged several limitations, including the use of a national patient database, which restricted their ability to control for prior diabetes management and preoperative glycemic control

This dual-pathway approach produces body composition changes that are faster and more complete than either peptide achieves independently

5 (Issue 11), 22503153 (2015)

Western blot analysis illustrated that sulforaphane increased the expression of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase (NQO1), the latter two of which are anti-oxidative enzymes